ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

PARIS, March 04, 2024 (GLOBE NEWSWIRE) --

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting rights
02/29/202471,751,20177,686,895

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,   

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980,

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment



EN
04/03/2024

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Financial Results for the Fourth Quarter and Full Ye...

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 •   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting •   Execution of strategic collaboration and investment agreements with AstraZeneca •   Cécile Chartier, Ph.D., appointed as a director of the Cellectis’ Board of Directors •   Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) •   Cash position of $156 million ...

April 29, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis publie ses résultats financiers du quatrième trimestre 2023 ...

Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023  •   Présentation de données préliminaires de l’essai clinique NATHALI-01 et de résultats cliniques actualisés de l’essai BALLI-01 lors de la réunion annuelle de l’American Society of Hematology (ASH) •   Signature d’un accord de collaboration stratégique et d'accords d’investissement avec AstraZeneca •   Nomination du docteur Cécile Chartier, Ph.D. au conseil d’administration •   Tirage de la deuxième tranche de 15 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Eu...

April 29, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Effi...

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell ...

April 22, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis présente de nouveaux procédés d’éditions par TALEN® permetta...

Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs) Cette nouvelle approche d'édition pourrait être utilisée pour développer de nouveaux traitements pour les maladies métaboliques et neurologiquesL'utilisation d'ADN simple brin circulaire associée à l'édition du génome par TALEN® permet d’obtenir des niveaux élevés d'insertion génique dans les CSPHs sans affecter leur viabilité et leur capacité à se différencier NEW YORK, 22 avr. 2024 (GLOBE ...

April 22, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Tre...

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloi...

April 10, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch